Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy [Yahoo! Finance]
Lundquist Investigator Dr. Ashraf Ibrahim Is the Lead Author in the Landmark Study on Pioneering Oral Fungal Infection Treatment Showing Promise in Preclinical Trials [Yahoo! Finance]
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Matinas BioPharma Prices $10 Million Registered Direct Offering [Yahoo! Finance]